Tissue microarray analysis of topoisomerase IIα protein in gastric adenocarcinomas: Histogenetic and prognostic implications

Cancer Genomics and Proteomics

Volumn 8, Issue 3, 2011, Pages 127-133

  Wang, Gangshi ^a   Huang, Haili ^a   Gao, Jie ^a   Chen, Ping ^b   You, Weidi ^a   Wu, Benyan ^a   Wang, Mengwei ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Gastric carcinoma; Prognosis; Tissue microarray; Topoisomerase II

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER SURVIVAL; CANCER TISSUE; FEMALE; HISTOGENESIS; HUMAN; HUMAN TISSUE; LIFESTYLE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; STOMACH EPITHELIUM; STOMACH MUCOSA; SURVIVAL RATE; SURVIVAL TIME; TISSUE MICROARRAY;

EID: 79956357334     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Kelley JR and Duggan JM: Gastric cancer epidemiology and risk factors. J Clin Epidemiol 56: 1-9, 2003. (Pubitemid 36183309)
2. Pozzo C and Barone C: Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents? Oncologist 13: 794-806, 2008.
3. Liu W, Zhang X and Sun W: Developments in treatment of esophageal/gastric cancer. Curr Treat Options Oncol 9: 375-387, 2008.
4. Moretti E, Oakman C and Di Leo A: Predicting anthracycline benefit: Have we made any progress? Curr Opin Oncol 21: 507-515, 2009.
5. Wagner AD, Grothe W, Haerting J et al: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24: 2903-2909, 2006. (Pubitemid 46630593)
6. Holden JA, Perkins SL, Snow GW and Kjeldsberg CR: Immunohistochemical staining for DNA topoisomerase II in non-Hodgkin's lymphomas. Am J Clin Pathol 104: 54-59, 1995.
7. Yabuki N, Sasano H, Kato K et al: Immunohistochemical study of DNA topoisomerase II in human gastric disorders. Am J Pathol 149: 997-1007, 1996. (Pubitemid 26334183)
8. Schrader C, Meusers P, Brittinger G et al: Topoisomerase II alpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome. Leukemia 18: 1200-1206, 2004.
9. Provencio M, Corbacho C, Salas C et al: The topoisomerase II alpha expression correlates with survival in patients with advanced Hodgkin's lymphoma. Clin Cancer Res 9: 1406-1411, 2003. (Pubitemid 36418394)
10. Nakopoulou L, Lazaris AC, Kavantzas N et al: DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. Pathobiology 68: 137-143, 2000. (Pubitemid 32110322)
11. O'Malley FP, Chia S, Tu D et al: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 101: 644-650, 2009.
12. Chen WY, Mao WM, Zhao L et al: Expression of P-gp, GST-pi and Topo II alpha in gastric and colorectal cancers and their clinical significance. Zhonghua Zhong Liu Za Zhi 27: 738-740, 2005.
13. Ferrandina G, Petrillo M, Carbone A et al: Prognostic role of topoisomerase-II alpha in advanced ovarian cancer patients. Br J Cancer 98: 1910-1915, 2008.
14. Wong N, Yeo W, Wong WL et al: TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int J Cancer 124: 644-652, 2009.
15. Maruya S, Shirasaki T, Nagaki T et al: Differential expression of topoisomerase II alpha protein in salivary gland carcinomas: histogenetic and prognostic implications. BMC Cancer 9: 72, 2009.
16. Cuadros M, Dave SS, Jaffe ES et al: Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas. J Clin Oncol 25: 3321-3329, 2007. (Pubitemid 47325619)
17. Holden JA, Snow GW, Perkins SL, Jolles CJ and Kjeldsberg CR: Immunohistochemical staining for DNA topoisomerase II in frozen and formalin-fixed paraffin-embedded human tissues. Mod Pathol 7: 829-834, 1994.
18. D'Andrea MR, Farber PA and Foglesong PD: Immunohistochemical detection of DNA topoisomerase II alpha and II beta compared with detection of Ki-67, a marker of cellular proliferation in human tumors. Appl Immunohistochem 2: 177-185, 1994.
19. Ye YW, Shi YQ, Wang CM, Li BZ and Zhu L: Differential expression of immunohistochemical markers between cardiac carcinoma and carcinoma in antrum of stomach and correlation thereof with clinicopathological factors. Zhonghua Yi Xue Za Zhi 89: 962-966, 2009.
20. Shi H, Lu D, Shu Y et al: Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma. Cancer Invest 26: 344-351, 2008. (Pubitemid 351601390)
21. Fogt F, Nikulasson ST, Holden JA et al: Topoisomerase II alpha expression in normal, inflammatory, and neoplastic conditions of the gastric and colonic mucosa. Mod Pathol 10: 296-302, 1997. (Pubitemid 27228876)
22. Coleman LW, Bronstein IB and Holden JA: Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas. Anticancer Res 21: 1167-1172, 2001.
23. Varis A, Zaika A, Puolakkainen P et al: Coamplified and overexpressed genes at ERBB2 locus in gastric cancer. Int J Cancer 109: 548-553, 2004. (Pubitemid 38339645)
24. Liang Z, Zeng X, Gao J et al: Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. BMC Cancer 8: 363, 2008.
25. Skarlos DV, Bai M, Goussia A et al: Expression of a molecular marker panel as a prognostic tool in gastric cancer patients treated postoperatively with docetaxel and irinotecan. A study of the Hellenic Cooperative Oncology Group. Anticancer Res 27: 2973-2983, 2007. (Pubitemid 47228031)
26. Liu JM, Chen LT, Li AF et al: Prognostic implications of the expression of erbB2, topoisomerase II alpha and thymidylate synthase in metastatic gastric cancer after fluorouracil-based therapy. Jpn J Clin Oncol 34: 727-732, 2004. (Pubitemid 41615269)
27. Moelans CB, de Weger RA, van Blokland MT et al: Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer. Mod Pathol 23: 62-70, 2010.
28. Tanner M, Hollmen M, Junttila TT et al: Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16: 273-278, 2005. (Pubitemid 40309309)
29. Yu GZ, Chen Y and Wang JJ: Overexpression of GRB2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol 135: 1331-1339, 2009.
30. Mano MS, Rosa DD, De Azambuja E et al: The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours. Cancer Treat Rev 33: 64-77, 2007. (Pubitemid 46132005)
31. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000. (Pubitemid 30046295)